Literature DB >> 25022601

Autoimmune manifestations in patients with Waldenström macroglobulinemia.

Bruno Bockorny1, Jonessa A Atienza2, Constantin A Dasanu3.   

Abstract

Waldenström macroglobulinemia represents a lymphoplasmacytic lymphoma with an indolent clinical course. The existing literature associates this hematologic malignancy with various autoimmune disorders. Notwithstanding, these autoimmune conditions have not been comprehensively characterized or systematized to date. As a result, their clinical implications remain largely unknown. The authors offer a comprehensive review of the existing literature on various hematologic and nonhematologic autoimmune disorders documented in the course of Waldenström macroglobulinemia. Whereas some of them are thought to be secondary to a dysfunctional immune response associated with an underlying malignant process, others might be primary and might even play a role in its pathogenesis. Moreover, the observations that personal history and family history of certain autoimmune diseases were associated with an increased risk of subsequent Waldenström macroglobulinemia strengthen further the hypothesis that shared susceptibility genes and chronic antigenic stimulation might predispose individuals to both conditions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disorder; Autoimmune hemolytic anemia; Lymphoplasmacytic lymphoma; Peripheral neuropathy; Rheumatologic diseases

Mesh:

Year:  2014        PMID: 25022601     DOI: 10.1016/j.clml.2014.04.009

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  5 in total

1.  Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation.

Authors:  Hiroaki Tanaka; Chihiro Kuwabara; Yusuke Isshiki; Yoshio Suzuki
Journal:  BMJ Case Rep       Date:  2018-12-13

2.  Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.

Authors:  L Rotenstein; A Nathan; I Ghobrial; J Antin; A Parnes
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

3.  Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Authors:  Jad Othman; Emma Verner; Constantine S Tam; Jane Huang; Leo Lin; James Hilger; Judith Trotman; Robin Gasiorowski
Journal:  Haematologica       Date:  2018-02-08       Impact factor: 9.941

4.  Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Authors:  Kavita M Dhodapkar; Madhav V Dhodapkar; Akhilesh Kaushal; Ajay K Nooka; Allison R Carr; Katherine E Pendleton; Benjamin G Barwick; Julia Manalo; Samuel S McCachren; Vikas A Gupta; Nisha S Joseph; Craig C Hofmeister; Jonathan L Kaufman; Leonard T Heffner; Stephen M Ansell; Lawrence H Boise; Sagar Lonial
Journal:  Blood Cancer Discov       Date:  2021-09-01

5.  Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy.

Authors:  Kim Ma; Stephen Caplan
Journal:  Case Rep Hematol       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.